Programmable antibiotic delivery to combat methicillin-resistant Staphylococcus aureus through precision therapy.

Area of Science:

• Biomedical Engineering
• Infectious Diseases
• Drug Delivery Systems

Background:

• Multidrug-resistant bacterial pathogens, such as methicillin-resistant Staphylococcus aureus (MRSA), pose a significant global health threat, necessitating novel therapeutic strategies.
• Bacterial virulence factors are key to infection processes, and targeting these factors offers a promising avenue for developing new treatments.
• The ability of some bacteria to induce plasma clotting is a critical step in colonization and can be exploited for therapeutic purposes.

Purpose of the Study:

• To develop a programmable antibiotic delivery system for precision therapy against MRSA.
• To utilize MRSA's intrinsic virulence factors, coagulase and staphylokinase, to trigger sequential antibiotic release from functionalized microspheres.
• To demonstrate the system's selectivity, efficacy in bacterial clearance, and performance in a preclinical wound healing model.

Main Methods:

• Design and synthesis of fibrinogen-functionalized porous microspheres.
• Utilizing MRSA-secreted coagulase to cleave fibrinogen and trigger microsphere collapse.
• Employing staphylokinase to hydrolyze fibrin, leading to further antibiotic release.
• Evaluating the system's selectivity against MRSA versus other bacteria.
• Assessing in vivo efficacy in a rat wound healing model.

Main Results:

• The developed system demonstrated high selectivity, distinguishing between live or dead MRSA and other bacterial species.
• The programmable microspheres achieved 99% clearance of MRSA within 4 hours in vitro.
• The system showed enhanced efficiency in promoting wound healing in a rat model.
• The sequential triggered-release mechanism effectively delivered antibiotics based on bacterial presence.

Conclusions:

• This study presents a programmable drug delivery platform that precisely targets bacterial pathogens via their enzymatic cascades.
• The system offers a potential strategy for combating MRSA and other multidrug-resistant infections.
• The approach minimizes collateral damage to the microbiota, reducing selective antibiotic pressure.
• This programmable platform holds promise for future clinical applications in infectious disease therapy.